Molecular Neurodegeneration

official impact factor 5.36

Open Access Research article

An exo-cell assay for examining real-time γ-secretase activity and inhibition

Christopher C Shelton3,1, Yuan Tian4,1, Mark G Frattini2 and Yue-Ming Li3,1*

Author Affiliations

1 Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA

2 Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA

3 Department of Pharmacology, Weill Graduate School of Medical Sciences of Cornell University, New York, NY 10021, USA

4 Department of Physiology, Biophysics and Systems Biology, Weill Graduate School of Medical Sciences of Cornell University, New York, NY 10021, USA

For all author emails, please log on.

Molecular Neurodegeneration 2009, 4:22 doi:10.1186/1750-1326-4-22

Published: 2 June 2009

Abstract

γ-Secretase is an aspartyl protease that cleaves multiple substrates that are involved in broad biological processes ranging from stem cell development to neurodegeneration. The investigation of γ-secretase has been limited by currently available assays that require genetic or biochemical manipulation in the form of substrate transfection or membrane preparation. Here we report an exo-cell assay that is capable of characterizing γ-secretase activity in any cellular system without limitation. Using a highly active, recombinant substrate this assay can quickly and easily ascertain the status of γ-secretase activity in cell systems and patient samples. We have applied this method to determine the activity of γ-secretase in primary cell samples where transfection and/or membrane isolation are not viable options. Importantly, it allows for the detection of real time γ-secretase activity after inhibitor or drug treatment. The application of this assay to determine the role of γ-secretase in physiological and pathological conditions will greatly facilitate our characterization of this complex protease and help in the development and evaluation of γ-secretase-targeted therapies in Alzheimer's disease or a variety of neoplasms.